Zimmer Holdings diskutieren

Zimmer Holdings

Seit 5 Wochen stabiler Aufwärtstrend, aus meiner Sicht besteht weiteres Potential bis ca. 41 €.

Einer der globalen Marktführer in der orthopädischen Industrie, die Produktlinien EASYMIX und EASYMIX PRO in Europa und ausgewählten internationalen Märkten vertreiben. Erst kürzlich hatte Zimmer mit der Vermarktung der Produktlinie des orthopädischen Knochenzements HI-FATIGUE begonnen, welche von aap bio implants entwickelt und hergestellt wird.

Übersetzung fehlgeschlagen

Ersatzteile

Schöner Kursverlauf, Marktmacht und stetige Dividende - sehr schön!

Equities research analysts at Barclays lifted their price objective on shares of Zimmer Holdings from $128.00 to $130.00 in a research note issued to investors on Friday. The firm currently has an “overweight” rating on the stock. Barclays’ target price would suggest a potential upside of 14.08% from the company’s current price.

In other Zimmer Holdings news, VP Chad F. Phipps sold 5,000 shares of Zimmer Holdings stock on the open market in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $112.00, for a total transaction of $560,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 

A number of other firms have also recently commented on ZMH. Analysts at Leerink Swann raised their price target on shares of Zimmer Holdings from $122.00 to $135.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Zimmer Holdings in a research note on Friday, October 31st. They now have a $115.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Zimmer Holdings in a research note on Wednesday, October 29th. They now have a $120.00 price target on the stock, up previously from $108.00. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $120.89.

Zimmer Holdings (NYSE:ZMH) traded up 1.66% during mid-day trading on Friday, hitting $115.85. The stock had a trading volume of 272,946 shares. Zimmer Holdings has a 1-year low of $89.62 and a 1-year high of $114.98. The stock’s 50-day moving average is $108.5 and its 200-day moving average is $103.8. The company has a market cap of $19.620 billion and a P/E ratio of 24.51.

Zimmer Holdings (NYSE:ZMH) last released its earnings data on Thursday, October 23rd. The company reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.00 by $0.04. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company posted $1.25 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts expect that Zimmer Holdings will post $6.05 EPS for the current fiscal year. 

Zimmer Holdings, Inc (NYSE:ZMH) designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products.

Erfolgreich

Die Erfolgsstory von Zimmer geht weiter.

Zimmer Holdings (NYSE:ZMH) has received a consensus recommendation of “Buy” from the twenty brokerages that are covering the stock, AR Network reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $129.61.

A number of analysts have recently weighed in on ZMH shares. Analysts at Zacks reiterated a “neutral” rating and set a $126.00 price target on shares of Zimmer Holdings in a research note on Friday. Analysts at Argus raised their price target on shares of Zimmer Holdings from $116.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Analysts at Jefferies Group upgraded shares of Zimmer Holdings from a “hold” rating to a “buy” rating and raised their price target for the stock from $119.00 to $131.00 in a research note on Tuesday, February 3rd. Finally, analysts at Deutsche Bank raised their price target on shares of Zimmer Holdings from $107.00 to $114.00 and gave the company a “hold” rating in a research note on Monday, February 2nd.

gerihouse stimmt der Fundamentalanalyse mit dem Ergebnis 'unterbewertet' zu

gerihouse stimmt am 03.09.2015 der Fundamentalanalyse mit dem Ergebnis unterbewertet zu.

Wird wieder Zeit für Zimmer Aktien!

Der amerikanische Medizintechniker Zimmer Biomet (ISIN: US98956P1021, NYSE: ZBH) wird unverändert 0,22 US-Dollar Dividende auszahlen. Im Jahr 2014 haben sich die Firmen Biomet und Zimmer Holdings auf einen Zusammenschluss beider Unternehmen geeinigt.

Zimmer Holdings wurde 1927 gegründet und bietet orthopädische Implantate wie Knie-, Hüft- oder Zahnimplantate an. Der Konzern wurde im Jahr 2001 von Bristol-Myers Squibb abgetrennt und startete im April 2012 mit der Ausschüttung einer Dividende (0,18 US-Dollar). Im März 2014 wurde eine Anhebung der vierteljährlichen Auszahlung um zehn Prozent auf den aktuellen Betrag angekündigt.

Auf das Gesamtjahr hochgerechnet werden 0,88 US-Dollar ausgeschüttet. Damit liegt die derzeitige Dividendenrendite bei 0,88 Prozent beim aktuellen Börsenkurs von 99,57 US-Dollar (Stand: 24. August 2015). Die nächste Auszahlung erfolgt am 30. Oktober 2015 (Record day: 30. September 2015).

Redaktion MyDividends.de

Zimmer ;-)

Aloha

SecteurEquipement, fournitures et distribution médicale Agenda 01/02 | 12:00 Publication de résultats

Zimmer Biomet Holdings est spécialisée dans la conception, la fabrication et la commercialisation d'implants de reconstruction orthopédique et dentaire, d'implants rachidiens et de produits de traumatologie. Les produits de la famille de produits se répartissent comme suit:

- implants de reconstruction (59%): implants du genou (59,3% du CA) et implants de la hanche (40,7%);

- produits chirurgicaux et de traumatologie (21,8%);

- implants rachidiens (9,7%);

- implants dentaires (5,3%);

- autres (4,2%): notamment dispositifs chirurgicaux orthopédiques et instruments utilisés lors de la rééducation post-opératoire.

A fin 2017, le groupe dispose de 25 sites de production implantés dans le monde.

La répartition géographique du CA est la suivante: Amériques (62,2%), Europe-Moyen Orient-Afrique (22,3%) et Asie-Pacifique (15,5%).